GU Cancers 2024 | Real-world evaluation of nadofaragene firadenovec in BCG-Unresponsive NMIBC

Siamak Daneshmand, MD, University of Southern California, Los Angeles, CA, discusses the trial design of the ABLE-41 study (NCT06026332), which will assess the real-world effectiveness, and safety of nadofaragene firadenovec, an intravesical gene therapy, in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC). The primary objective is to assess the complete response rate, with secondary outcomes including patterns of use, survival, experiences of patients, caregivers, and physicians, as well as safety. This large, prospective registry will provide insights into the early utilization and outcomes of nadofaragene firadenovec in a real-world setting. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.